


a ERY22





b ERY27






FIG. 1



GPC3_ERY22_rCE115
GPC3_ERY27_hCE115
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
Antibody concentration (nM)

FIG. 2



GPC3_ERY22_rCE115
GPC3_ERY27_hCE115
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
-40
0.001
0.01
0.1
1
10
Antibody concentration (nM)

FIG. 3



a
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
Antibody concentration (nM)
1
2
3
4
b
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
Antibody concentration (nM)
1
5
6
7
8

FIG. 4



a
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
Antibody concentration (nM)
1
13
14
15
16
b
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
Antibody concentration (nM)
1
17
18
19
20

FIG. 5



a
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
Antibody concentration (nM)
1
21
22
23
24
b
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
Antibody concentration (nM)
1
25
26
27
28

FIG. 6



a
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
Antibody concentration (nM)
1
29
30
31
32
b
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
Antibody concentration (nM)
1
33
31
32
30

FIG. 7



a
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
Antibody concentration (nM)
1
30
34
33
35
b
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
Antibody concentration (nM)
1
34
35
36
37

FIG. 8



a
Cell growth inhibition rate (%)
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
Antibody concentration (nM)
1
30
34
35
37
b
Cell growth inhibition rate (%)
Antibody concentration (nM)
1
34
37
30
38

FIG. 9



a
Tumor volume (mm3)
1200
1000
800
600
400
200
0
10
20
30
40
50
Days after transplantation
Solvent
37
34
30
1
b
Tumor volume (mm3)
1600
1400
1200
1000
800
600
400
200
0
10
20
30
40
50
60
Days after transplantation
Solvent
37
38

FIG. 10



a
Tumor volume (mm3)
2500
2000
1500
1000
500
0
10
20
30
Days after transplantation
Solvent
1
30
34
33
35
b
Tumor volume (mm3)
4000
3500
3000
2500
2000
1500
1000
500
0
10
20
30
40
Days after transplantation
Solvent
37
34
30
1

FIG. 11



Kabat 1 2
EU index 1-2---------3---------4---------5---------6---------7---------8---------9---------0---------1---------2--
8-0---------0---------0---------0---------0---------0---------0---------0---------0---------0---------0--
IgG1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD-
IgG2 ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERK--CC
IgG3 ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLG
IgG4 ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG--
Kabat 2
EU index 2---------3---------4---------5---------6---------7---------8
2-----8---------0---------0---------0---------0---------0---------0
IgG1 -KTHTCPP----------CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
IgG2 -V-E-CPP----------CPAPPVA-GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVD
IgG3 DTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVD
IgG4 ---PPCPS----------CPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVD
Kabat 2 3
EU index 8---------9---------0---------1---------2---------3---------4---------5---------6---------7---------8-----
1---------0---------0---------0---------0---------0---------0---------0---------0---------0---------0-----
IgG1 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG
IgG2 GVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG
IgG3 GVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSG
IgG4 GVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
Kabat 3 4
EU index 8---9---------0---------1---------2---------3---------4
6---0---------0---------0---------0---------0---------0-------7
IgG1 QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:23)
IgG2 QPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:24)
IgG3 QPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK (SEQ ID NO:25)
IgG4 QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:26)

FIG. 12




Kabat CDR H1
Chothia CDR H1
Contact CDR H1
Kabat CDR H2
Chothia CDR H2
Contact CDR H2
Antibody name
CE115HA000
TR01HC40
TR01HC71
TR01HC82
TR01HC84
TR01H109
TR01H113
H0000
H0810
GCH054
GCH085
GCH094

FIG. 13-1



Antibody name	108	109	110	111	112	113
CE115HA000	T	V	T	V	S	S
TR01H040	T	V	T	V	S	S
TR01H071	T	V	T	V	S	S
TR01H082	T	V	T	V	S	S
TR01H084	T	V	T	V	S	S
TR01H109	T	V	T	V	S	S
TR01H113	T	V	T	V	S	S
H0000	L	V	T	V	S	S
H0610	L	V	T	V	S	S
GCH054	L	V	T	V	S	S
GCH055	L	V	T	V	S	S
GCH094	L	V	T	V	S	S

FIG. 13-2



Kabat CDR L1
Chothia CDR L1
Contact CDR L1
Antibody name
Kabat CDR L2
Chothia CDR L2
Contact CDR L2
Kabat CDR L3
Chothia CDR L3
Contact CDR L3

FIG. 14